within Pharmacolibrary.Drugs.C_CardiovascularSystem.C08E_NonSelectiveCalciumChannelBlockers.C08EX02_Perhexiline;

model Perhexiline
  extends Pharmacolibrary.Drugs.ATC.C.C08EX02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>name:</td><td>Perhexiline</td></tr><tr><td>ATC code:</td><td>C08EX02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Perhexiline is an antianginal agent that inhibits carnitine palmitoyltransferase-1 and -2, thereby modulating cardiac metabolism. It was used for the management of angina pectoris and some other cardiovascular indications but its use dropped sharply due to concerns of hepatotoxicity and neuropathy; in some countries it remains available under restricted conditions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in adult patients with angina pectoris, after oral administration, steady-state, mixed male and female, normal hepatic and renal function.</p><h4>References</h4><ol><li><p>Gould, BJ, et al., &amp; Parke, DV (1986). Stereoselective pharmacokinetics of perhexiline. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 16(5) 491â€“502. DOI:<a href=\"https://doi.org/10.3109/00498258609050254\">10.3109/00498258609050254</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3739369/\">https://pubmed.ncbi.nlm.nih.gov/3739369</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Perhexiline;
